Payment overview · 2025
General Payments
$1,132.73
50 reported records · 15 companies
Healthcare provider profile · identity verified
Fredric J Mintz, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SYOSSET, NY · NPI 1194759530
Verified facts
What the public records show
CMS Open Payments records show Fredric J Mintz, M.D. received $1,132.73 in general payments during 2025 across 50 reported records.
AstraZeneca Pharmaceuticals LP accounted for 34.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $386.41 | 34.1% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $194.96 | 17.2% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $90.44 | 8.0% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $74.99 | 6.6% | 4 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $73.04 | 6.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $59.49 | 5.2% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $44.58 | 3.9% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $42.91 | 3.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.52 | 2.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.78 | 2.5% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $28.76 | 2.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.54 | 1.9% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $21.31 | 1.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.20 | 1.7% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $16.80 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,132.73 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $281.49 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $191.11 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $139.31 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $115.73 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $90.44 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $74.99 | 4 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $73.04 | 3 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $67.98 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $44.58 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $42.91 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $42.91 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.18 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.52 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $28.78 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $28.78 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $28.78 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $28.76 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $16.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 60 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
60 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 349 | 97 |
| Alprazolam | Alprazolam | 282 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 271 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 244 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 199 | 53 |
| Losartan Potassium | Losartan Potassium | 199 | 54 |
| Sertraline Hcl | Sertraline Hcl | 182 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 180 | 34 |
| Simvastatin | Simvastatin | 168 | 45 |
| Gabapentin | Gabapentin | 166 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 35 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 110 | 12 |
| Metformin Hcl Er | Metformin Hcl | 104 | 31 |
| Omeprazole | Omeprazole | 102 | 38 |
| Azithromycin | Azithromycin | 98 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 26 |
| Famotidine | Famotidine | 91 | 23 |
| Montelukast Sodium | Montelukast Sodium | 91 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 20 |
| Bupropion Xl | Bupropion Hcl | 78 | 21 |
| Clonazepam | Clonazepam | 78 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 74 | suppressed |
| Potassium Chloride | Potassium Chloride | 70 | 23 |
| Meloxicam | Meloxicam | 69 | 21 |
| Trazodone Hcl | Trazodone Hcl | 69 | 19 |
| Allopurinol | Allopurinol | 65 | 18 |
| Furosemide | Furosemide | 65 | 23 |
| Synthroid | Levothyroxine Sodium | 60 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 11 |
| Lisinopril | Lisinopril | 57 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 55 | 15 |
| Glimepiride | Glimepiride | 54 | 15 |
| Atenolol | Atenolol | 52 | 13 |
| Eliquis | Apixaban | 52 | 11 |
| Metformin Hcl | Metformin Hcl | 49 | 15 |
| Buprenorphine Hcl | Buprenorphine Hcl | 48 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Methylprednisolone | Methylprednisolone | 47 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 47 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 12 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 41 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 33 |
| Ramipril | Ramipril | 36 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 23 |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 14 |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | 11 |
| Cefdinir | Cefdinir | 29 | 24 |
| Jardiance | Empagliflozin | 29 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | suppressed |
| Prednisone | Prednisone | 29 | 18 |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Carisoprodol | Carisoprodol | 21 | 11 |
| Meclizine Hcl | Meclizine Hcl | 21 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Oxycontin | Oxycodone Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,132.73 · 50 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, BRIXADI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, FARXIGA, GARDASIL 9, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Kerendia, Leqembi, MOUNJARO, Ozempic, PREVNAR 20, SHINGRIX, SPRAVATO, SUBLOCADE, SYNTHROID, TRELEGY ELLIPTA, UBRELVY, Wegovy, XIFAXAN, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error